Toward Targeted Treatment Strategies for Mantle Cell Lymphoma

Cancer research · Mantle cell lymphoma

Mantle cell lymphoma is a rare, typically aggressive B‑cell non‑Hodgkin lymphoma that often presents at an advanced stage and carries substantial long‑term mortality despite therapeutic advances.

Mantle cell lymphoma is a rare, typically aggressive B‑cell non‑Hodgkin lymphoma that often presents at an advanced stage and carries substantial long‑term mortality despite therapeutic advances. The study described clinical characteristics, treatment patterns, and overall survival of patients with mantle cell lymphoma managed at a high‑complexity referral center in Colombia from 2016 to 2025. Among 41 patients, 43.9% were younger than 65 years; most presented with Ann Arbor stage IV disease and high‑risk MIPI scores. First‑line therapy differed by age: younger patients more frequently received Nordic regimens, while older patients received R‑bendamustine. Response rates were similar across age groups. Overall survival did not differ by sex, age group, Ann Arbor stage, or LDH levels, but was significantly predicted by MIPI category (p=0.017). The study highlights the importance of prognostic indices and functional status assessment in routine practice.

Understanding the real‑world clinical characteristics, treatment patterns, and survival in mantle cell lymphoma improves prognostication and informs context‑adapted management strategies, particularly in middle‑income settings where data are scarce.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals